Rocket Lab's Waiting Game: Neutron Delays and Iridium Financing Keep Investors on Edge
Published on 07/18/2026 at 15:32 | Redaktion boerse-global.de
Investors in Rocket Lab USA are navigating two sharply different stories at once. On one hand, the space company has struck an $8 billion deal to buy Iridium Communications — a move analysts have called transformative. On the other, its flagship Neutron rocket keeps slipping down the timeline, and a freshly initiated neutral rating from Piper Sandler this week sent shares tumbling more than 12% on July 16. The stock closed Friday at $67.62, a modest 0.4% gain for the day but 55.2% below the record high of $151 it notched on May 27.
That gap between the May peak and current levels reflects a market that has stopped pricing Rocket Lab as a pure-play space operator and started treating it as an arbitrage play on a complex, debt-funded takeover. The Iridium acquisition values each share of the target at $54 in cash and stock, and Rocket Lab has already secured a $3.6 billion bridge financing facility — 2.4 times the company's cash and securities at the end of March. The deal's collar structure, which protects both sides from excessive stock swings, has a lower bound of $67.50. Shares briefly slipped below that threshold during the week's sell-off before recovering, leaving the deal spread at 14.4%.
The central question for holders is no longer simply where the stock goes next, but whether Rocket Lab can deliver the first Neutron flight in the fourth quarter of 2026 — its second delay in just over a year — while simultaneously financing and integrating an $8 billion acquisition. The company itself has warned that technical complexity could cause further slippage. A fuel-tank failure back in January was the immediate cause of the most recent pushback from the first quarter to the final quarter of next year.
Yet the operational side of the business continues to generate genuine momentum. Rocket Lab recently passed the System Requirements Review for the Space Development Agency's Tracking Layer Tranche 3 constellation, a contract worth roughly $816 million. That adds to a previously secured Transport Layer Beta award of about $515 million, bringing total SDA commitments to more than $1.3 billion. The Neutron program itself logged a full-power test of the second stage using the AVac engine. And the US Space Force's VICTUS-HAZE mission — a tactically responsive space contract requiring rapid launch and orbital rendezvous — was completed successfully.
Should investors sell immediately? Or is it worth buying Rocket Lab USA?
Those achievements helped lift second-quarter revenue to $200.3 million, a 63.5% year-over-year increase, and pushed gross margin to 38.2%. The backlog now stands at $2.2 billion, with the Space Systems segment accounting for 68% of revenue. Citizens analyst Trevor Walsh, citing the Iridium deal as a catalyst for moving Rocket Lab into higher-value space applications, raised his price target from $95 to $130 and maintained an "Outperform" rating. Roth Capital's Suji Desilva also set a $130 target with a "Buy" rating, calling the combination a transformative step that positions Rocket Lab as a fully integrated space-infrastructure provider.
Contrast that with Piper Sandler's Alexander Potter, who initiated coverage this week with a "Neutral" rating and an $83 target. Potter explicitly said he prefers rival AST SpaceMobile, citing a "cheaper valuation" and a clearer path to positive EBITDA. The market latched onto that cautious view, and the stock's 50-day moving average of $107.37 now sits far above the current price.
Technically, the relative strength index at 30.1 signals an oversold condition that often precedes a bounce. But the annualized 30-day volatility of 96.8% underscores how violently sentiment can shift in either direction. The broader analyst community remains broadly positive: 16 analysts average a "Buy" rating with a 12-month price target of $116.57, implying a 73% upside. A frequently cited valuation model projects 2029 revenue of $1.7 billion and net income of $167.5 million, yielding a fair value of $103.91.
Rocket Lab USA at a turning point? This analysis reveals what investors need to know now.
The near-term catalysts are now binary. If the Iridium deal's financing stays on terms that keep the stock within its collar structure, and Neutron completes its qualification tests without another public setback, the oversold position could serve as a launchpad for recovery. But if the bridge facility faces a snag or the first Neutron flight gets delayed a third time, the 52-week low of $37.57 could come back into play. The next milestones: progress on Neutron qualification ahead of its planned fourth-quarter 2026 debut, and clearer detail on the Iridium deal's closing conditions in the coming quarters. Iridium itself reports second-quarter results on July 22, though the conference call has been canceled due to the pending acquisition — results will be posted directly to its investor-relations page.
Ad
Rocket Lab USA Stock: New Analysis - 18 July
Fresh Rocket Lab USA information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
